目的 重組人血管內(nèi)皮抑制素注射液聯(lián)合順鉑對(duì)肺癌惡性胸腔積液患者的治療效果，及對(duì)核糖核苷酸還原酶M1亞基（RRM1）表達(dá)水平的影響。方法 回顧性分析2016年1月-2017年10月在青島市城陽區(qū)人民醫(yī)院接受治療的肺癌惡性胸腔積液患者的臨床資料，根據(jù)其治療方式分為對(duì)照組和觀察組，對(duì)照組給予順鉑治療，觀察組給予重組人血管內(nèi)皮抑制素注射液聯(lián)合順鉑治療，1次/周，4周為1療程，每次用藥前放空胸腔積液。觀察兩組患者的治療效果，比較兩組患者治療前后腫瘤標(biāo)志物、胸腔積液RRM1表達(dá)水平和并發(fā)癥發(fā)生率的差異。結(jié)果 觀察組治療的有效率為97.50%，明顯高于對(duì)照組（82.50%）（P<0.05）。兩組患者治療前RRM1表達(dá)水平無差別；治療后，兩組RRM1表達(dá)水平均降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.001）；且觀察組RRM1表達(dá)水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.001）。兩組患者治療前腫瘤標(biāo)志物水平無明顯差異；治療后，兩組患者的癌胚抗原（CEA）、非小細(xì)胞肺癌相關(guān)抗原（CYFRA 21-1）、癌抗原19-9（CA19-9）和癌抗原125（CA125）水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.001）；且觀察組患者的CEA、CYFRA21-1、CA19-9和CA125水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.001）。兩組患者血液系統(tǒng)和消化道毒性，肝、腎功能損害發(fā)生率無明顯差別。結(jié)論 重組人血管內(nèi)皮抑制素注射液與順鉑對(duì)肺癌惡性胸腔積液患者有較好的治療效果，可明顯改善患者的腫瘤標(biāo)志物和RRM1表達(dá)水平，具有良好的應(yīng)用價(jià)值。

Objective To Endostar combined with cisplatin on malignant pleural effusion of lung cancer patients, and the influence on the expression of RRM1. Methods Retrospective analysis of clinical data of January 2016 to October 2017 in our hospital for treatment of malignant pleural effusion of lung cancer patients, according to the treatment methods are divided into control group and observation group, the control group was given cisplatin treatment, observation group received Endostar combined with cisplatin in the treatment. The therapeutic effects of the two groups were observed, and the difference of the tumor markers, the RRM1 expression level and the incidence of complications in the two groups before and after treatment were compared. Results In the observation group, the treatment efficiency was 97.50%, significantly higher than the control group (82.50%) (χ²=5.000, P=0.025); Before treatment, the expression level of RRM1 in the two groups of patients had no significant difference; After treatment, the observation group the expression level of RRM1 was lower than that of the control group (t=5.545, P<0.001); There was no significant difference in the level of tumor markers between the two groups before treatment. After treatment, the levels of CEA, CYFRA21-1, CA19-9 and CA125 in the observation group were lower than those in the control group (P<0.001). Two groups of patients with hematologic and gastrointestinal toxicity, liver and kidney function damage rate had no significant difference (χ²=0.082, P=0.775). Conclusion Endostar combined with cisplatin has a good therapeutic effect on lung cancer patients with malignant pleural effusion, can significantly improve the patient's tumor markers and the expression level of RRM1, has good application value.